NCT02894385View on ClinicalTrials.gov

Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 13, 2016

Primary Completion Date

April 10, 2017

Study Completion Date

December 15, 2017

Conditions
PharmacokineticsHepatic InsufficiencyRenal Insufficiency
Interventions
DRUG

BAY1841788

600 mg single dose, administered as 2 x 300 mg tablets on Day 00.

Trial Locations (2)

23538

Lübeck

24105

Kiel

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Orion Corporation, Orion Pharma

INDUSTRY

lead

Bayer

INDUSTRY